CD20 antigen imaging with124I-rituximab PET/CT in patients with rheumatoid arthritis

Human Antibodies

Volumn 20, Issue 1-2, 2011, Pages 29-35

  Tran, L ^a   Huitema, A D R ^a   Van Rijswijk, M H ^a   Dinant, H J ^a   Baars, J W ^b   Beijnen, J H ^a,c   Vogel, W V ^b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; IODINE 124; RITUXIMAB; RITUXIMAB I 124; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SYNOVIAL MEMBRANE; THYROID GLAND; TISSUE DISTRIBUTION; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 79955867299     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-2011-0239     Document Type: Article

References (42)

1. T. Shaw, J. Quan and M.C. Totoritis, B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience, Ann Rheum Dis 62(Suppl 2) (2003), ii55-ii59.
2. F. Wolfe and M.A. Cathey, The assessment and prediction of functional disability in rheumatoid arthritis, J Rheumatol 18 (1991), 1298-1306.
3. M.M. Ward, Clinical measures in rheumatoid arthritis: which are most useful in assessing patients? J Rheumatol 21 (1994), 17-27. (Pubitemid 24044911)
4. G.A. Bruyn, E. Naredo, I. Moller, C. Moragues, J. Garrido, G.H. de Bock, M.A. d'Agostino, E. Filippucci, A. Iagnocco, M. Backhaus, W.A. Swen, P. Balint, C. Pineda, S. Milutinovic, D. Kane, G. Kaeley, F.J. Narvaez, R.J. Wakefield, J.A. Narvaez, J. de Augustin and W.A. Schmidt, Reliability of ul-trasonography in detecting shoulder disease in patients with rheumatoid arthritis, Ann Rheum Dis 68 (2009), 357-361.
5. U.M. Dohn, B.J. Ejbjerg, M. Hasselquist, E. Narvestad, J. Moller, H.S. Thomsen and M. Ostergaard, Detection of bone erosions in rheumatoid arthritis wrist joints with magnetic resonance imaging, computed tomography and radiography, Arthritis Res Ther 10 (2008), R25.
6. E.H. Elzinga, C.J. van der Laken, E.F. Comans, A.A. Lam-mertsma, B.A. Dijkmans and A.E. Voskuyl, 2-Deoxy-2-fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis, Mol Imaging Biol 9 (2007), 357-360.
7. Z. Zhang and S.L. Bridges, Jr., Pathogenesis of rheumatoid arthritis. Role of B lymphocytes, Rheum Dis Clin North Am 27 (2001), 335-353. (Pubitemid 32488709)
8. J. Voswinkel, K. Weisgerber, M. Pfreundschuh and A. Gause, The B lymphocyte in rheumatoid arthritis: recirculation of B lymphocytes between different joints and blood, Autoimmuni-ty 31 (1999), 25-34. (Pubitemid 32457782)
9. D.G. Maloney, A.J. Grillo-Lopez, C.A. White, D. Bodkin, R.J. Schilder, J.A. Neidhart, N. Janakiraman, K.A. Foon, T.M. Liles, B.K. Dallaire, K. Wey, I. Royston, T. Davis and R. Levy, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood 90 (1997), 2188-2195. (Pubitemid 27392702)
10. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens and T. Shaw, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N Engl J Med 350 (2004), 2572-2581. (Pubitemid 38758544)
11. S.B. Cohen, P. Emery, M.W. Greenwald, M. Dougados, R.A. Furie, M.C. Genovese, E.C. Keystone, J.E. Loveless, G.R. Burmester, M.W. Cravets, E.W. Hessey, T. Shaw and M.C. Totoritis, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks, Arthritis Rheum 54 (2006), 2793-2806. (Pubitemid 44497758)
12. P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska, J. Schechtman, L. Szczepanski, A. Kavanaugh, A.J. Racewicz, R.F. van Vollenhoven, N.F. Li, S. Agarwal, E.W. Hessey and T.M. Shaw, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial, Arthritis Rheum 54 (2006), 1390-1400.
13. P.J. Perik, M.N. Lub-de Hooge, J.A. Gietema, W.T. van der Graaf, M.A. de Korte, S. Jonkman, J.G. Kosterink, D.J. van Veldhuisen, D.T. Sleijfer, P.L. Jager and E.G. de Vries, Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer, J Clin Oncol %20;24 (2006), 2276-2282. (Pubitemid 46630657)
14. S.T. Gmeiner, J. Fettich, S. Zver, I. Mlinaric-Rascan, S. Hojker, A. Socan, P.K. Peitl and S. Mather, 99mTc-labelled rit-uximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience, Nucl Med Commun 29 (2008), 1059-1065.
15. T.M. Behr, B. Wormann, M. Gramatzki, J. Riggert, S. Gratz, M. Behe, F. Griesinger, R.M. Sharkey, H.J. Kolb, W. Hid-demann, D.M. Goldenberg and W. Becker, Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies, Clin Cancer Res 5 (1999), 3304s- 3314s. (Pubitemid 29493931)
16. P. Blauenstein, J.T. Locher, K. Seybold, H. Koprivova, G.A. Janoki, H.R. Macke, P. Hasler, A. Ammann, I. Novak-Hofer, A. Smith, Experience withtheiodine-123andtechnetium-99m labelled anti-granulocyte antibody MAb47: a comparison of labelling methods, Eur J Nucl Med 22 (1995), 690-698.
17. G.A. Wiseman, B. Leigh, W.D. Erwin, D. Lamonica, E. Korn-mehl, S.M. Spies, D.H. Silverman, T.E. Witzig, R.B. Sparks and C.A. White, Radiation dosimetry results for Zevalin ra-dioimmunotherapy of rituximab-refractory non-Hodgkin lym-phoma, Cancer 94 (2002), 1349-1357. (Pubitemid 34150898)
18. D.M. van der Heijde and J.W. Jacobs, The original "DAS" and the "DAS28" are not interchangeable: comment on the articles by Prevoo et al., Arthritis Rheum 41 (1998), 942-945.
19. L. Tran, J.W. Baars, H.J. Maessen, C.A. Hoefnagel, J.H. Beij-nen and A.D. Huitema, A simple and safe method for 131I ra-diolabeling of rituximab for myeloablative high-dose radioim-munotherapy, Cancer Biother Radiopharm 24 (2009), 103-110.
20. T.M. Illidge, M. Bayne, N.S. Brown, S. Chilton, M.S. Cragg, M.J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, M. Zivanovic and P.W. Johnson, Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy, Blood 113 (2009), 1412-1421.
21. A. Rosset, L. Spadola and O. Ratib, OsiriX: an open-source software for navigating in multidimensional DICOM images, J Digit Imaging 17 (2004), 205-216. (Pubitemid 40378992)
22. D.M. van der Heijde and J.W. Jacobs, The original "DAS" and the "DAS28" are not interchangeable: comment on the articles by Prevoo et al, Arthritis Rheum 41 (1998), 942-945.
23. M.M. Ward, Clinical measures in rheumatoid arthritis: which are most useful in assessing patients? J Rheumatol 21 (1994), 17-27. (Pubitemid 24044911)
24. F. Wolfe, S.M. Kleinheksel, M.A. Cathey, D.J. Hawley, P.W. Spitz and J.F. Fries, The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis, J Rheumatol 15 (1988), 1480-1488. (Pubitemid 18263094)
25. T. Pincus, Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis, Bull NYU Hosp Jt Dis 66 (2008), 216-223.
26. P. Roben, R. Barkmann, S. Ullrich, A. Gause, M. Heller and C.C. Gluer, Assessment of phalangeal bone loss in patients with rheumatoid arthritis by quantitative ultrasound, Ann Rheum Dis 60 (2001), 670-677. (Pubitemid 32588370)
27. G. Levy, C. Chow, M.A. Cimmino and W.A. Schmidt, RA Imaging Study Group: which imaging in rheumatoid arthritis? Joint Bone Spine 76 (2009), 438-439.
28. G. Levy, C. Chow, M.A. Cimmino and W.A. Schmidt, RA Imaging Study Group: which imaging in rheumatoid arthritis? Joint Bone Spine 76 (2009), 438-439.
29. P. Youinou, T.E. Taher, J.O. Pers, R.A. Mageed and Y. Re-naudineau, B lymphocyte cytokines and rheumatic autoimmune disease, Arthritis Rheum 60 (2009), 1873-1880.
30. C.C. Reparon-Schuijt, W.J. van Esch, C. van Kooten, N.P. Ezendam, E.W. Levarht, F.C. Breedveld and C.L. Verweij, Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis, Arthritis Rheum 44 (2001), 2029-2037. (Pubitemid 33644045)
31. S.T. Gmeiner, J. Fettich, S. Zver, I. Mlinaric-Rascan, S. Hojker, A. Socan, P.K. Peitl and S. Mather, 99mTc-labelled rit-uximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience, Nucl Med Commun 29 (2008), 1059-1065.
32. L.R. Perk, O.J. Visser, M. Stigter-van Walsum, M.J. Vosjan, G.W. Visser, J.M. Zijlstra, P.C. Huijgens and G.A. van Dongen, Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography, Eur J Nucl Med Mol Imaging 33 (2006), 1337-1345. (Pubitemid 44630790)
33. D.G. Maloney, A.J. Grillo-Lopez, C.A. White, D. Bodkin, R.J. Schilder, J.A. Neidhart, N. Janakiraman, K.A. Foon, T.M. Liles, B.K. Dallaire, K. Wey, I. Royston, T. Davis and R. Levy, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood 90 (1997), 2188-2195. (Pubitemid 27392702)
34. S. Krapp, Y. Mimura, R. Jefferis, R. Huber and P. Sondermann, Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity, J Mol Biol 325 (2003), 979-989. (Pubitemid 36263407)
35. A. Brouwers, P. Mulders, E. Oosterwijk, W. Buijs, F. Corstens, O. Boerman and W. Oyen, Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies, Cancer Biother Radiopharm 19 (2004), 466-477. (Pubitemid 39281337)
36. I.J. Burvenich, S. Schoonooghe, P. Blanckaert, K. Bacher, L. Vervoort, E. Coene, N. Mertens, F. De Vos and G. Slegers, Biodistribution and planar gamma camera imaging of (123)I-and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor, Nucl Med Biol 34 (2007), 257-265. (Pubitemid 46441854)
37. T. Carter, K. Sterling-Levis, K. Ow, L. Doughty, M. Hattarki, D. Shapira, D. Hewish, A.A. Kortt and P.J. Russell, Biodis-tributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody, Cancer Immunol Immunother 53 (2004), 533-542. (Pubitemid 38680260)
38. J. Pijpe, G.W. van Imhoff, F.K. Spijkervet, J.L. Roodenburg, G.J. Wolbink, K. Mansour, A. Vissink, C.G. Kallenberg and H. Bootsma, Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study, Arthritis Rheum 52 (2005), 2740-2750. (Pubitemid 41369102)
39. R. J. Looney, J. H. Anolik, D. Campbell, R. E. Felgar, F. Young, L. J. Arend, J. A. Sloand, J. Rosenblatt and I. Sanz, B cell depletion as a novel treatment for systemic lupus ery-thematosus: a phase I/II dose-escalation trial of rituximab, Arthritis Rheum 50 (2004), 2580-2589. (Pubitemid 39062719)
40. J. C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D. R. Close, R. M. Stevens and T. Shaw, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N Engl J Med 350 (2004), 2572-2581. (Pubitemid 38758544)
41. N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence-Bruckler, D. Maloney, M. Czuczman, D. Green, J. Rosenberg, P. McLaughlin and D. Shen, Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann Oncol 9 (1998), 995-1001. (Pubitemid 28496709)
42. P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, M.E. Williams, M.R. Heyman, I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain, A.D. Ho, J. Lister, K. Wey, D. Shen and B.K. Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapyfor relapsed indolentlymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol 16 (1998), 2825-2833. (Pubitemid 28363048)